Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Cellectis S.A.NASDAQ: CLLS

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash growth accelerates

Q1 FY2026 net change in cash of $28.58M (cash outflow) rose 83.0% year over year, ahead of the -2129.6% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -4.8% a year.

Context

  • Net change in cash amounted to 109.2% of revenue in FY2025, up 93.4 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +83.0% holds above the trailing-twelve-month pace of -2129.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$28.58M-407.6% QoQ
Last fiscal yearDec 2025
-$79.67M-1317.6% YoY
LTMMar 2026
-$94.68M-2129.6% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+83.0%——
1 year-1317.6%——
3-year CAGR-4.8%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(79.67M) USD
Year-over-year change
-1317.6%

Net Change in Cash vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2129.6% is the lowest of 10, against a peer median of +112.1%.
  • Net change in cash amounts to 139.1% of revenue for CLLS, versus a peer median of 262.0%.
CLLS Competitors
Net Change in Cash for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DBVTDBV Technologies S.A.LTM Mar 2026$216.21M USD+344.1%+7.0%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$156.79M USD+274.7%——
ANROAlto Neuroscience, Inc.LTM Mar 2026$103.01M USD+330.7%-28.6%—
CLLSCellectis S.A.LTM Mar 2026$94.68M USD-2129.6%-4.8%139.1%
SLNSilence Therapeutics plcLTM Mar 2026$59.21M USD—+49.3%6425.7%
MREOMereo BioPharma Group plcLTM Mar 2026$26.26M USD-290.0%-21.3%5252.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$14.65M USD+134.8%——
AMRNAmarin Corporation plcLTM Mar 2026$11.44M USD+112.1%—5.3%
ACIUAC Immune S.A.LTM Dec 2025CHF 9.36M CHF-77.8%-54.0%262.0%
KRROKorro Bio, Inc.LTM Mar 2026$1.45M USD-98.1%-7.4%37.7%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$1M USD-185.5%-61.2%—
Peer median (excluding CLLS) —+112.1%-21.3%262.0%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(96.75M)(98.69M)(116.84M)(36.7M)(67.8M)
Depreciation & Amortization14.16M18.44M18.52M19.84M20.12M
Deferred Income Tax087K371K00
Stock-Based Compensation11.49M6.04M5.23M00
Change in Working Capital(12.3M)(5.72M)(3.99M)53.57M(41.72M)
Accounts Receivables(12.44M)(8.99M)2.25M(6.72M)(4.44M)
Inventory215K0000
Accounts Payables177K3.25M(6.31M)2.05M(3.27M)
Other Working Capital(252K)23K67K58.24M(34.01M)
Other Non-Cash Items(21.17M)(7.6M)71.95M(14.61M)49.26M
Operating Cash Flow(104.56M)(87.44M)(24.75M)22.1M(40.14M)
Capital Expenditures(18.56M)(2.44M)(1.07M)(2.58M)(2.37M)
Acquisitions (Net)00000
Purchases of Investments(143K)00(162.48M)(160.27M)
Sales of Investments15M126K063.69M134.24M
Other Investing Activities10.97M(456K)(14.44M)00
Investing Cash Flow7.28M(2.76M)(15.51M)(102.63M)(29.58M)
Debt Repayment(10.64M)(6.6M)24.56M18.17M(5.4M)
Common Stock Issued44.64M067.94M82.68M44.14K
Common Stock Repurchased0(569K)000
Dividends Paid00000
Other Financing Activities13.53M8.32M(9.64M)(11.04M)(10.85M)
Financing Cash Flow47.53M1.15M82.87M89.8M(16.2M)
Effect of Forex Changes(5.75M)(3.36M)884K(2.73M)6.24M
Net Change in Cash(55.51M)(92.42M)43.49M6.54M(79.67M)
Free Cash Flow(123.12M)(89.89M)(25.82M)19.52M(42.5M)

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.